Gluetacs Therapeutics
PrivateLast Round
Series A
May 31, 2024
Total Funding Raised
$20.6M
Company Overview
Gluetacs Therapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series A round in May 2024.
Gluetacs Therapeutics is a biotechnology company that specializes in the development of small molecule oral protein degraders for the treatment of oncology and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gluetacs Therapeutics Comparables
Compare Gluetacs Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GluBio Therapeutics | 89% | |
| HealZen Therapeutics Co., Ltd. | 88% | |
| Shanghai Leadingtac Pharmaceutical Co., Ltd. | 88% |
For institutional investors. Book with your work email.
Gluetacs Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Gluetacs Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gortune Investment | Series A |
Gluetacs Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Gluetacs Therapeutics's valuation, stock price, and market status.
Is Gluetacs Therapeutics a public or private company?
Gluetacs Therapeutics is a private company.
What is the current stock price of Gluetacs Therapeutics?
Gluetacs Therapeutics is a private company, so its shares have no public market price. Caplight tracks Gluetacs Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Gluetacs Therapeutics worth (valuation)?
Valuation information for Gluetacs Therapeutics is not publicly available.
Can I buy Gluetacs Therapeutics stock?
Gluetacs Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Gluetacs Therapeutics's last funding round?
Gluetacs Therapeutics's most recent funding round was Series A on May 31, 2024.
Who are the main investors in Gluetacs Therapeutics?
Key investors in Gluetacs Therapeutics include Gortune Investment.
Will Gluetacs Therapeutics IPO soon?
No public IPO plans have been announced for Gluetacs Therapeutics.
How can I track Gluetacs Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Gluetacs Therapeutics's shares on secondary markets.